These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 3213269)

  • 1. [Effectiveness and limits of D-penicillamine therapy].
    Behrend T; Eisterhues C; Behrend M
    Z Rheumatol; 1988; 47 Suppl 1():28-33. PubMed ID: 3213269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current status of D-penicillamine therapy in chronic polyarthritis].
    Franke M; Menning H; Ströbel G
    Z Rheumatol; 1981; 40(2):54-61. PubMed ID: 7282106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA].
    Minami M; Kaneda K
    Ryumachi; 1995 Oct; 35(5):780-91. PubMed ID: 8594657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
    Bandilla K; Missler B; Klein-Reesink B
    Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibodies to D-penicillamine in patients with chronic polyarthritis--diagnostic aid in undesired and insufficient drug effects?].
    Storch W; Keitel W
    Z Rheumatol; 1988; 47 Suppl 1():44-7. PubMed ID: 3213272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [D-penicillamine in the treatment of rheumatoid polyarthritis. 104 cases with a 5-year follow-up].
    Valat JP; Fouquet B; Eveleigh MC; Chantreuil C; Lalot F
    Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):7-12. PubMed ID: 3704516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period.
    Capell HA; Marabani M; Madhok R; Torley H; Hunter JA
    Q J Med; 1990 Apr; 75(276):335-44. PubMed ID: 1974723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [5-year treatment of rheumatoid polyarthritis with D-penicillamine].
    Duquesnoy B; Cocheteux P; Siame JL; Delcambre B
    Sem Hop; 1983 May; 59(21):1641-4. PubMed ID: 6310780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
    Hakoda M; Taniguchi A; Kamatani N; Akahoshi T; Kashiwazaki S
    J Rheumatol; 1994 Sep; 21(9):1637-41. PubMed ID: 7799341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH; Bingham SJ; Bryer D; Emery P
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular disorders associated with D-penicillamine treatment for rheumatoid arthritis.
    Devogelaer JP; Isaac G; Noël H; De Bruyère M; Huaux JP; Nagant de Deuxchaisnes C
    Int J Clin Pharmacol Res; 1985; 5(3):143-7. PubMed ID: 4018948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylprednisolone pulse therapy in conjunction with azathioprine in rheumatoid arthritis.
    Bijlsma JW; Schenk Y; Ramselaar AC; Huber-Bruning O
    Clin Rheumatol; 1986 Dec; 5(4):499-504. PubMed ID: 3816097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose weekly oral methotrexate therapy for inflammatory arthritis.
    Boh LE; Schuna AA; Pitterle ME; Adams EM; Sundstrom WR
    Clin Pharm; 1986 Jun; 5(6):503-8. PubMed ID: 3720217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects of d-penicillamine in the treatment of rheumatoid arthritis].
    Mazzanti G; Paladini G; Damiani D; Bianchini D; Florean M; Mesesnel E; Cataldo R
    Minerva Med; 1986 May; 77(22-23):1009-16. PubMed ID: 2941698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D; Smolen JS
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
    Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
    Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [D-penicillamine--side effects, pathogenesis and decreasing the risks].
    Grasedyck K
    Z Rheumatol; 1988; 47 Suppl 1():17-9. PubMed ID: 3063003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.